影像学方法在临床中晚期非小细胞肺癌治疗方案规划和疗效监测中的应用价值

Lung cancer ranks the first with the highest morbidity and mortality in China. Non-small-cell lung cancer (NSCLC) accounts for 80%-85% of all lung cancer cases. Because the pathogenesis of pancreatic cancer is concealed, 70%~80% patients were diagnosed in advanced or late stage, and the effects of operation on them were poor. The present predominant management for advanced NSCLC is radiotherapy or chemotherapy. Radiology, especially the emerging of molecular imaging, helps doctors effectively to make treatment plan management and monitor therapy response. The combination of molecular imaging and traditional radiology enable overlay of molecular characters onto the structural, pathological and pathophysiological background of cancer. Besides evaluating the location, size, clinical staging and pathologic grading of disease, molecular imaging combined with traditional radiology also makes it possible to diagnose and predict lung cancer more fully, to plan and adjust therapy strategy personally (especially for targeted molecular therapy) and to monitor the early therapy response, and thus guide clinical practice in lung cancer more fully, more timely, more accurately and more effectively. This review summarized the current state and the latest developments on the application of molecular imaging combined with traditional radiology in the therapy management and/or efficacy monitoring of surgery, radiotherapy and chemotherapy for lung cancer.